Atirmociclib vs SHR-6209

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: CDK4 · full HR+/HER2- Metastatic Breast Cancer pipeline

Atirmociclib

Developed by Pfizer

Phase 3 in HR+/HER2- Metastatic Breast Cancersmall molecule
Partial signal

NCT06465368 · Phase 2 · completed

The study randomized 121 participants to PF-07220060 plus letrozole or letrozole alone, but it was open-label, with only the biopsy assessment performed centrally in a blinded manner. Its primary endpoint was a Ki-67-based biomarker rather than a clinical outcome, and although the reported percentages favored the combination, statistical significance for the primary comparison was not stated.

Next expected readout: December 2026 · NCT06239467 (registry estimate)

Reported efficacy

Percentage of Participants With Complete Cell Cycle Arrest (CCCA) at Day 14: Percentage of Participants With Complete Cell Cycle Arrest (CCCA) at Day 14 (Day 14): PF-07220060 + Letrozole 88.2% (95% CI 76.6-94.5) vs Letrozole Alone 17.9% (95% CI 10.0-29.8) (unclear)

Result source: NCT06465368

SHR-6209

Developed by Jiangsu Hengrui Pharmaceuticals

Phase 3 in HR+/HER2- Metastatic Breast Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT06974929 (registry estimate)

No aligned efficacy figure on record for this race.

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAtirmociclibSHR-6209
PFS, median—Trial running · NCT06760637—Trial running · NCT07894328
OS, median—Trial running · NCT06760637—Trial running · NCT07894328
ORR—Trial running · NCT06760637—Trial running · NCT07894328
Clinical benefit rate—Trial running · NCT06760637—Trial running · NCT07894328

PFS, median

Atirmociclib
—Trial running · NCT06760637
SHR-6209
—Trial running · NCT07894328

OS, median

Atirmociclib
—Trial running · NCT06760637
SHR-6209
—Trial running · NCT07894328

ORR

Atirmociclib
—Trial running · NCT06760637
SHR-6209
—Trial running · NCT07894328

Clinical benefit rate

Atirmociclib
—Trial running · NCT06760637
SHR-6209
—Trial running · NCT07894328
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

SHR-6209: no structured comparison results are available for HR+/HER2- Metastatic Breast Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Atirmociclib: 3 of 4 rows · SHR-6209: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAtirmociclib
Dropout rate
0%a
NCT06465368 · Phase 2 · combination
Discontinued due to AEs
—a
NCT06465368 · Phase 2 · combination
Serious AEs
1.7%a
NCT06465368 · Phase 2 · combination
Most frequent reported AEs
a
diarrhoea 18.6%
nausea 13.6%
asthenia 10.2%
NCT06465368 · Phase 2 · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Atirmociclib

Complete Cell Cycle Arrest 88.2% (n=51) vs 17.9% (n=56) Letrozole @ 2wk
responder rate · % of participants
NCT06465368 · Phase 2 · combination
Ki67 -30.12% (n=49) vs -17.27% (n=54) Letrozole @ 2wk
absolute change · percentage points
NCT06465368 · Phase 2 · combination
show 1 more result
-97.277% (n=49) vs -72.414% (n=54) Letrozole @ 2wk*
NCT06465368 · Phase 2 · combination · converted to % from 97.277 Percentage reduction as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Atirmociclib's landscape · SHR-6209's landscape